摘要
目的 探讨利培酮治疗首发精神分裂症的适宜剂量。方法 12 6例首发精神分裂症患者随机分 4组 (每组 30例 ) ,分别以 2mg/d(2mg组 )、3mg/d(3mg组 )、4mg/d(4mg组 )、5mg/d(5mg组 )利培酮治疗 ,疗程均为 12周。于治疗前及治疗第 1,2 ,4 ,6 ,8,12周末分别进行阳性和阴性症状量表 (PANSS)、临床总体印象量表、治疗中需处理的不良反应量表、锥体外系不良反应量表评分 ,比较 4个组的疗效及不良反应。结果 治疗第 12周末 ,各组PANSS总分减分率在各组间的差异无显著性 ,2mg组阴性症状分低于其他 3组 ,差异有非常显著性 (P <0 0 1)。显效率 :2mg组为 6 7% ,3mg组为87% ,4mg组为 77% ,5mg组为 77% ,各组间差异无显著性。不良反应以锥体外系反应 (EPS)占首位 ,EPS发生率 2mg组为 17% ,3mg组为 6 7% ,4mg组为 93% ,5mg组为 97% ;2 ,3mg组较 4mg、5mg组的EPS发生少且轻 ,差异有非常显著性 (P <0 0 1)。结论 不同剂量利培酮治疗首发精神分裂症的总体疗效的差异无显著性 ,2mg/d对阴性症状群的疗效明显差于 3mg/d、4mg/d、5mg/d。 2mg/d、3mg/d的EPS发生明显少、轻于 4mg/d、5mg/d。利培酮治疗首发精神分裂症的适宜剂量为 3mg/d。
Objective The purpose of this study was to explore the optimum dosage of risperidone in treatment of first-episode schizophrenia. Methods All 126 first-episode patients with schizophrenia diagnosed according to CCMD-3 criteria were randomly assigned to being treated with fixed daily doses of 2 mg,3 mg,4 mg or 5 mg of risperidone. The symptoms were assessed with the Positive and Negative Symptom Scale (PANSS) and Clinical Global Impression at baseline and at the 1st,2nd,4th,6th,8th,and 12th weekend,and the side effects assessed with the Treatment Emergent Symptom Scale and the Extrapyramidal Symptom. Results Altogether 120 patients finished the study. After 12-week treatment,there were no significant differences among the different dosage group according to the PANSS total score. The negative symptom score was significant lower in the 2 mg/d group compared with other three groups. There was no significant difference of the response rates among all groups. The EPS was most common side effect,which was milder in 2 mg and 3 mg groups than in other groups. Conclusions It is recommended that the risperidone dose of 3 mg/d is optimum in treatment of first-episode schizophrenia for the definite efficacy with milder side effect.
出处
《中华精神科杂志》
CAS
CSCD
北大核心
2004年第1期26-29,共4页
Chinese Journal of Psychiatry
